Peter A. Pinto, MD, presented “The Manogram: Role of MRI in Prostate Cancer Screening” during the 2022 Frontiers in Oncologic Prostate Care and Ablative Local Therapy symposium on September 23, 2022, in Los Angeles, California.
How to cite: Pinto, Peter A. “The Manogram: Role of MRI in Prostate Cancer Screening.” September 23, 2022. Accessed Nov 2024. https://grandroundsinurology.com/the-manogram-role-of-mri-in-prostate-cancer-screening/
The Manogram: Role of MRI in Prostate Cancer Screening – Summary
Peter A. Pinto, MD, Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute in Bethesda, Maryland, discusses the utility of MRI in prostate cancer screening. He begins by describing how early screening tools such as digital rectal exams and PSA often resulted in overdiagnosis and overtreatment, leading some physicians to decry the role of screening. Dr. Pinto underscores that over 30,000 men still die of prostate cancer yearly, and physicians should not discount the value of screening as part of an ongoing effort to save lives. He then reviews the foundational studies, including PROMIS and the IP1-PROSTAGRAM, that illustrate the effectiveness of MRI in diagnosing prostate cancer over TRUS. When compared with other screening tools MRI has high sensitivity and specificity, is well-tolerated by patients, and provides actionable information. The biggest detractor for MRI has been the cost. In response to this, Dr. Pinto discusses using biparametric MRI (bpMRI) over multiparametric MRI (mpMRI) which is faster and less expensive. Before concluding, Dr. Pinto looks to other cancers where imaging is used in screening to further illustrate that while no tool is perfect, the value exceeds the cost. Furthermore, Dr. Pinto contends that physicians can continue to improve screening by risk-stratifying men who should undergo MRI, evaluating options such as bpMRI, and better understanding screening intervals.
The annual symposium on Frontiers in Oncologic Prostate Care and Ablative Local Therapy (FOCAL) is an outstanding program on prostate imaging, transperineal interventions, and ablative treatments for prostate cancer and benign prostatic hyperplasia. Bringing together community-based, academic, and industry partners, FOCAL offers lectures by world-renowned faculty and hands-on training workshops on in-office transperineal interventions, fusion-guided prostate ablation and state-of-the-art BPH management with novel technologies. For more educational activities from the symposium that took place from September 23-24, 2022 in Los Angeles, California, visit our collection page.
ABOUT THE AUTHOR
Peter A. Pinto, MD, is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute in Bethesda, Maryland. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute at Johns Hopkins Hospital in Baltimore, Maryland. Dr. Pinto is a board-certified urologic surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.
